Key Highlights
- AngioDynamics delivered record fiscal fourth quarter and full-year 2026 results, marking its seventh consecutive period of double-digit Med Tech segment expansion and achieving full-year pro forma profitability.
- Annual pro forma net sales climbed 9.4% to $320.2 million, driven by an 18.4% surge in Med Tech revenue to $150.0 million, alongside a more modest 2.5% increase in Med Device sales.
- Adjusted EBITDA reached $13.2 million for the year, while adjusted EPS came in at a loss of $0.24.
- The company maintains a debt-free balance sheet with $53.9 million in cash, and issued fiscal year 2027 guidance forecasting net sales between $336.0 million and $341.0 million and adjusted EBITDA of $13.0 million to $16.0 million.
AngioDynamics, Inc. (NASDAQ: ANGO) delivered record fiscal fourth quarter and full-year 2026 results, marking the company's seventh consecutive period of double-digit growth in its Med Tech segment and, notably, achieving full-year pro forma profitability for the first time in this reporting period. The consistency of the Med Tech segment's growth trajectory across seven straight periods underscores a durable, rather than one-off, improvement in the company's core growth engine.
For the full fiscal year, pro forma net sales climbed 9.4% to $320.2 million, a growth rate driven predominantly by an 18.4% surge in Med Tech revenue to $150.0 million. This strong Med Tech performance more than offset a comparatively modest 2.5% increase in Med Device sales, illustrating how the company's growth story has become increasingly concentrated in its higher-growth Med Tech portfolio relative to its more mature Med Device business.
Profitability metrics showed continued improvement alongside the top-line growth, with adjusted EBITDA reaching $13.2 million for the full year. Adjusted earnings per share came in at a loss of $0.24, indicating that while the company has achieved pro forma profitability on an EBITDA basis, it has not yet reached positive adjusted EPS, a distinction that reflects the impact of depreciation, amortization, interest, and other below-the-line items on the company's bottom-line results.
A central driver behind the Med Tech segment's growth has been the company's NanoKnife platform, which saw a striking 64.5% revenue spike in the fourth quarter alone. This acceleration followed the implementation of Category I CPT codes and a favorable Palmetto GBA Medicare local coverage determination covering prostate and liver indications, both significant reimbursement milestones that materially improve the commercial pathway for NanoKnife procedures by providing clearer billing codes and confirmed Medicare coverage for physicians performing these procedures.
AngioDynamics maintains a debt-free balance sheet with $53.9 million in cash, a financial position that provides meaningful flexibility as the company continues to invest in its growth initiatives. The company also recently received FDA Investigational Device Exemption (IDE) approval for its RELIEF BPH study, adding a new clinical development program to its pipeline targeting benign prostatic hyperplasia.
Looking ahead, AngioDynamics issued fiscal year 2027 guidance forecasting net sales between $336.0 million and $341.0 million, representing continued growth from the $320.2 million achieved in fiscal 2026, alongside adjusted EBITDA guidance of $13.0 million to $16.0 million. This guidance range suggests management expects continued momentum in the Med Tech segment, particularly NanoKnife, to remain the primary driver of growth into the new fiscal year.






Please wait processing your request...